155 related articles for article (PubMed ID: 37715074)
1. Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N; Ghadiri F; Sahraian MA; Nahayati MA; Moghadasi AN; Langroodi HG; Poursadeghfard M; Hosseini S; Heidari H; Baghbanian SM; Kamali H; Ameli Z; Shahmohammadi S; Navardi S
Acta Neurol Belg; 2024 Feb; 124(1):205-212. PubMed ID: 37715074
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
3. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Hartung HP; Berger T; Bermel RA; Brochet B; Carroll WM; Holmøy T; Karabudak R; Killestein J; Nos C; Patti F; Ross AP; Vanopdenbosch L; Vollmer T; Buffels R; Garas M; Kadner K; Manfrini M; Wang Q; Freedman MS
Mult Scler Relat Disord; 2020 Nov; 46():102492. PubMed ID: 33039944
[TBL] [Abstract][Full Text] [Related]
4. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Vollmer TL; Cohen JA; Alvarez E; Nair KV; Boster A; Katz J; Pardo G; Pei J; Raut P; Merchant S; MacLean E; Pradhan A; Moss B
Mult Scler Relat Disord; 2020 Nov; 46():102454. PubMed ID: 33045496
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.
Hartung HP;
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503093
[TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
9. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
10. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C
Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
Bove R; Hellwig K; Pasquarelli N; Borriello F; Dobson R; Oreja-Guevara C; Lin CJ; Zecevic D; Craveiro L; McElrath T; Vukusic S
Mult Scler Relat Disord; 2022 Aug; 64():103963. PubMed ID: 35753176
[TBL] [Abstract][Full Text] [Related]
13. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
15. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Barrera B; Simpson H; Engebretson E; Sillau S; Valdez B; Parra-González J; Winger RC; Epperson LA; Banks A; Pierce K; Spotts M; O'Gean K; Alvarez E; Gross R; Piquet AL; Schreiner T; Corboy JR; Pei J; Vollmer TL; Nair KV
Ann Clin Transl Neurol; 2023 Apr; 10(4):579-588. PubMed ID: 36811392
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Stahnke AM; Holt KM
Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
20. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]